EMPAA L 25/5MG TAB 28s

• Brand: Empaa‑L, produced by Horizon Pharmaceuticals (Pvt.) Ltd. in Pakistan.

• Active Ingredients per Tablet:

  • Empagliflozin 25 mg (SGLT2 inhibitor)

  • Linagliptin 5 mg (DPP‑4 inhibitor)
    
    

• Form: Film-coated tablet; pack size typically 28 tablets.
  

🩺 Therapeutic Use

This fixed‑dose combination is prescribed for type 2 diabetes mellitus when diet and exercise alone do not adequately control blood glucose. It works by:

• Empagliflozin: Enhances urinary glucose excretion.

• Linagliptin: Inhibits DPP‑4 enzyme, increasing incretin hormones to boost insulin secretion and reduce glucagon.
  Additional benefits include potential for weight reduction, modest blood pressure lowering, and cardiovascular risk reduction in diabetic patients.
  

📌 Dosage & Administration

• Dosage: One tablet once daily, preferably in the morning. May be taken with or without food. Do not crush or chew the tablet.
  

Individual regimens may vary based on clinical response and concomitant therapy—always follow your healthcare provider’s instructions.

⚠️ Side Effects & Warnings

Common Side Effects:

• Genital and urinary tract infections, such as yeast infections, balanitis, vulvovaginitis

• Increased urination, thirst, nasopharyngitis, rash, itching, headache

• Potential hypoglycemia when used with insulin or sulfonylureas